The market has been neutral on Karyopharm Therapeutics Inc (KPTI) stock recently. KPTI gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.
Karyopharm Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on KPTI!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With KPTI Stock Today?
Karyopharm Therapeutics Inc (KPTI) stock has fallen -1.91% while the S&P 500 is up 1.41% as of 3:30 PM on Friday, Oct 6. KPTI has fallen -$0.02 from the previous closing price of $1.31 on volume of 715,391 shares. Over the past year the S&P 500 is up 14.14% while KPTI has fallen -78.25%. KPTI lost -$1.47 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Karyopharm Therapeutics Inc click here.
More About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Karyopharm's lead compound, XPOVIO(R) (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade(R) (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Click Here to get the full Stock Report for Karyopharm Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
